214 related articles for article (PubMed ID: 32866053)
1. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
[TBL] [Abstract][Full Text] [Related]
2. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
[TBL] [Abstract][Full Text] [Related]
8. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
10. Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19.
Reddy EK; Battula S; Anwar S; Sajith AM
Mini Rev Med Chem; 2021; 21(6):704-723. PubMed ID: 33185159
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Rommasi F; Nasiri MJ; Mirsaeidi M
Mol Cell Biochem; 2022 Mar; 477(3):711-726. PubMed ID: 35013850
[TBL] [Abstract][Full Text] [Related]
13. Baricitinib set to join the Covid-19 therapeutic arsenal?
Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
[No Abstract] [Full Text] [Related]
14. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
Dzobo K; Chiririwa H; Dandara C; Dzobo W
OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Vitiello A; Ferrara F
Mol Biol Rep; 2022 Jan; 49(1):827-831. PubMed ID: 34839450
[TBL] [Abstract][Full Text] [Related]
17. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Yadav AK; Wen S; Xu X; Yu L
Ann Palliat Med; 2021 Jan; 10(1):707-720. PubMed ID: 33440983
[TBL] [Abstract][Full Text] [Related]
18. Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.
Tufan A; Matucci-Cerinic M
Turk J Med Sci; 2021 Dec; 51(SI-1):3391-3404. PubMed ID: 34844296
[TBL] [Abstract][Full Text] [Related]
19. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.
Talukdar J; Bhadra B; Dattaroy T; Nagle V; Dasgupta S
Biomed Pharmacother; 2020 Dec; 132():110886. PubMed ID: 33113418
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
Lin Z; Niu J; Xu Y; Qin L; Ding J; Zhou L
J Med Virol; 2022 Apr; 94(4):1523-1534. PubMed ID: 34846766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
